CAMBRIDGE, Mass., Jan. 12, 2024 – Arena BioWorks announces its inauguration as a leading-edge biomedical research institute. With its mission firmly rooted in deciphering the mechanisms of human diseases and propelling technological innovations, Arena BioWorks is poised to transform these insights into lifesaving therapeutics through its internal biotech companies.


Co-Founders and Visionaries

The foundation of Arena BioWorks is underpinned by a distinguished group of co-founders. Stuart Schreiber, a renowned scientist from Harvard University and co-founder of the Broad Institute, joins forces with Steve Pagliuca, former Co-Chair of Bain Capital, and Tom Cahill of Newpath Partners, a life science venture capital firm. This trio brings a blend of scientific acumen and visionary leadership to the institute.


Core Scientific Team

The scientific endeavors at Arena BioWorks are spearheaded by leaders in their respective fields. Stuart Schreiber and Keith Joung lead the team, with other eminent scientists set to join. Their expertise in chemical biology and CRISPR gene editing is central to the institute’s innovative research trajectory.


Founding Investors

The institute’s initial phase has been made viable through the substantial backing of Steve Pagliuca, Michael Dell, Michael Chambers, Jim Breyer, and Elisabeth DeLuca. Their support establishes a foundational model for self-sustainability at Arena BioWorks.


Arena’s Novel Approach

Distinct in its operation, Arena BioWorks departs from conventional research models by utilizing a private funding approach. This strategy facilitates a swifter transition from insight discovery to practical application, free from the usual constraints of grant and venture capital dependencies. Arena BioWorks’ research encompasses a broad spectrum of diseases, harnessing a suite of advanced technologies including chemoproteomics, gene editing, and artificial intelligence.


Leadership and Impact

Under the stewardship of Stuart Schreiber, Steve Pagliuca, and Tom Cahill, Arena BioWorks is guided by an amalgamation of expertise in biotechnology, venture capitalism, and scientific innovation. The institute aspires to be a perpetual center of excellence, reinvesting its profits back into ongoing research and development. This innovative model sets a new standard in the biomedical research field.

About PackGene

PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.

Related News

Related Services

Plasmids GMP Services

Multiple scales & grade of solutions of various kind of plasmids suitable for multiple treatments in a fast and cost effective way.

AAV GMP Services

Ranging from small-scale AAV production, to large-scale AAV cGMP manufacturing for animal studies.
aav icon

Technology Platforms

PackGene’s proprietary π-Alpha™ 293 AAV High-yield Platform increases AAV production by 3 to 8 times that of traditional platforms.